Total Payments
$7,192
2024 Payments
$678.81
Companies
40
Transactions
190
Medicare Patients
8,023
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$3,664 (50.9%)
Consulting$3,300 (45.9%)
Education$228.03 (3.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,664 | 185 | 50.9% |
| Consulting Fee | $3,300 | 2 | 45.9% |
| Education | $228.03 | 3 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Global Kinetics USA Corporation | $3,300 | 2 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $489.73 | 14 | $0 (2022) |
| Celgene Corporation | $439.91 | 29 | $0 (2024) |
| Biogen, Inc. | $398.60 | 22 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $262.95 | 14 | $0 (2024) |
| Genentech USA, Inc. | $191.93 | 6 | $0 (2023) |
| ABBVIE INC. | $189.94 | 8 | $0 (2024) |
| UCB, Inc. | $173.45 | 7 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $155.11 | 8 | $0 (2024) |
| TG Therapeutics, Inc. | $151.32 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $678.81 | 27 | TG Therapeutics, Inc. ($151.32) |
| 2023 | $560.48 | 30 | Celgene Corporation ($254.67) |
| 2022 | $2,731 | 46 | Global Kinetics USA Corporation ($1,800) |
| 2021 | $2,188 | 43 | Global Kinetics USA Corporation ($1,500) |
| 2020 | $221.95 | 14 | E.R. Squibb & Sons, L.L.C. ($35.07) |
| 2019 | $349.15 | 18 | EMD Serono, Inc. ($63.88) |
| 2018 | $281.39 | 8 | Teva Pharmaceuticals USA, Inc. ($233.14) |
| 2017 | $181.74 | 4 | Teva Pharmaceuticals USA, Inc. ($144.49) |
All Payment Transactions
190 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $24.22 | General |
| Category: NEUROLOGY | ||||||
| 11/06/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $28.15 | General |
| Category: Neurology | ||||||
| 10/30/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: Narcoplepsy | ||||||
| 10/29/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: Neuropsychiatry | ||||||
| 09/10/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 09/09/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $6.96 | General |
| Category: Immunology | ||||||
| 09/09/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $3.95 | General |
| Category: Immunology | ||||||
| 08/21/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: Immunology | ||||||
| 08/02/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: Immunology | ||||||
| 07/11/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $31.62 | General |
| Category: Neurology | ||||||
| 07/02/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $25.63 | General |
| Category: Neuroscience | ||||||
| 06/27/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Neurology | ||||||
| 06/26/2024 | UCB, Inc. | Zilbrysq (Drug) | Food and Beverage | In-kind items and services | $34.19 | General |
| Category: Neurology | ||||||
| 06/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: Rare Disease | ||||||
| 06/12/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/21/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/14/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug), VYVGART | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Neurology | ||||||
| 05/08/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Neuropsychiatry | ||||||
| 05/01/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Neurology | ||||||
| 04/14/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $44.86 | General |
| Category: Neurology | ||||||
| 04/10/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: Neurology | ||||||
| 03/13/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: Neurology | ||||||
| 02/08/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $22.25 | General |
| 02/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 2,138 | 11,552 | $1.2M | $344,044 |
| 2022 | 15 | 2,026 | 13,083 | $1.1M | $332,684 |
| 2021 | 18 | 2,060 | 13,985 | $1.1M | $352,409 |
| 2020 | 17 | 1,799 | 7,749 | $860,432 | $239,542 |
Total Patients
8,023
Total Services
46,369
Medicare Billing
$1.3M
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 662 | 1,577 | $438,800 | $142,109 | 32.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 342 | 342 | $161,595 | $52,303 | 32.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 14 | 7,800 | $109,200 | $38,635 | 35.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 188 | 329 | $120,908 | $25,124 | 20.8% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 43 | 341 | $64,108 | $15,548 | 24.3% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 155 | 156 | $72,793 | $15,060 | 20.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 73 | 84 | $29,988 | $10,412 | 34.7% |
| 96139 | Administration of psychological or neuropsychological test by technician, each additional 30 minutes | Office | 2023 | 155 | 295 | $40,144 | $8,070 | 20.1% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 55 | 57 | $29,925 | $7,412 | 24.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 97 | 109 | $21,173 | $6,765 | 32.0% |
| 95908 | Nerve conduction, 3-4 studies | Office | 2023 | 78 | 78 | $28,298 | $6,015 | 21.3% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 53 | 53 | $23,651 | $5,437 | 23.0% |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 35 | 142 | $20,590 | $5,194 | 25.2% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 155 | 156 | $21,228 | $4,153 | 19.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $6,993 | $1,760 | 25.2% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 15 | 15 | $675.00 | $48.49 | 7.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 658 | 1,588 | $441,861 | $142,204 | 32.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 312 | 312 | $147,420 | $47,299 | 32.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 20 | 9,700 | $135,800 | $47,220 | 34.8% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 181 | 311 | $114,293 | $24,189 | 21.2% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2022 | 145 | 147 | $68,593 | $14,471 | 21.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 60 | 72 | $25,704 | $8,791 | 34.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 103 | 128 | $24,864 | $8,460 | 34.0% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 61 | 61 | $32,025 | $8,105 | 25.3% |
| 96139 | Administration of psychological or neuropsychological test by technician, each additional 30 minutes | Office | 2022 | 143 | 287 | $39,055 | $7,965 | 20.4% |
About Allen Gee, MD, PHD
Allen Gee, MD, PHD is a Neurology healthcare provider based in Cody, Wyoming. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083793863.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Allen Gee, MD, PHD has received a total of $7,192 in payments from pharmaceutical and medical device companies, with $678.81 received in 2024. These payments were reported across 190 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($3,664).
As a Medicare-enrolled provider, Gee has provided services to 8,023 Medicare beneficiaries, totaling 46,369 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Cody, WY
- Active Since 11/03/2006
- Last Updated 08/07/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1083793863
Products in Payments
- PERSONAL KINETIGRAPH (PKG) (Device) $1,500
- ZEPOSIA (Drug) $474.98
- KESIMPTA (Drug) $246.34
- ADUHELM (Biological) $230.48
- OCREVUS (Biological) $173.43
- UBRELVY (Drug) $162.44
- BRIUMVI (Drug) $151.32
- COPAXONE (Drug) $144.49
- Briviact (Drug) $97.84
- NURTEC ODT (Drug) $92.10
- BOTOX (Biological) $84.74
- ULTOMIRIS (Biological) $79.30
- TYSABRI (Biological) $78.89
- INGREZZA (Drug) $77.70
- VYEPTI (Biological) $76.48
- Leqembi (Drug) $65.39
- Mavenclad (Biological) $63.88
- AUSTEDO (Drug) $62.71
- SOLIRIS (Drug) $55.97
- VYVGART (Drug) $54.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.